RecruitingPhase 2NCT06730308

Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma

A Prospective, Single-arm Phase II Study of Glucocorticoids Combined With Concurrent Chemoradiotherapy for Unresectable Thymoma

Sponsor

Sun Yat-sen University

Enrollment

45 participants

Start Date

Nov 20, 2024

Study Type

INTERVENTIONAL

Conditions

Thymoma

Summary

This study aims to assess the efficacy of methylprednisolone combined with concurrent chemoradiotherapy in treating unresectable or recurrent thymoma.

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Concurrent chemotherapy, a drug called Methylprednisolone, and others for people with thymoma. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.